



Bimeda, Inc.
One Tower Lane, Suite 2250
Oakbrook Terrace, IL 60181 USA
Tel. (630) 928-0361
Fax. (630) 928-0362
www.bimeda.com

April 4, 2019

To Whom it May Concern:

Concerning recent events involving bisphosphonate use in horses, Bimeda, Inc., the FDA license-holder for Tildren™ (tiludronate disodium) would like to clarify our position regarding its use. As a company, we do not condone, nor have we ever supported, the use of bisphosphonates in an off-label manner, especially in horses under 4 years of age. It is our belief that bisphosphonates should only be used by veterinarians familiar with their use and their long-term effects and in the appropriate-aged horse.

At Bimeda, we are committed to the veterinary oath: “Do No Harm” and, in that light, we are cooperating with both AAEP and the Gluck Equine Research Center to study the effects of bisphosphonate use and to develop better testing methodology.

In the hands of trained veterinary professionals, bisphosphonates are a tremendously effective tool to improve the lives of horses suffering from navicular syndrome.

Tildren™ has 14-plus years history of use, with an impressive efficacy and safety profile when used properly. We welcome the recent partial bans proposed by racing organizations in the United States and Canada, regarding bisphosphonate use in young horses, and we are committed to research which will provide a better understanding of these important equine pharmaceuticals.

A handwritten signature in blue ink, appearing to read 'D. W. Ellefson', is written over a light blue rectangular background.

D. W. Ellefson, DVM
Director, Technical Services
Bimeda, Inc.